UTHRUnited Therapeutics Corporation
$549.48+32% 1Y
$549.48
$414.7352 weeks$596.76
UTHR in its own filings
Nothing in UTHR's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
526
Events found in the filings · across 4,388 filings · the record starts in 1999
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 8, 2026
Most recent filing · Form 8-K
- Record starts
- Aug 16, 1999
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Oct 28, 2026
- Material impairmenthistorical
- 2006-01-25
- SEC comment-letter activity44 occurrences
- 2023-12-13
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 8, 2026On September 8, 2026, United Therapeutics Corporation (the Company ) entered into an accelerated share repurchase agreement (the ASR Agreement ) with Citibank, N.A. ( Citi ) to repurchase approximately $477.6 million in the aggregate of the Company’s common stock ( Common Stock ) under the Company’s previously …Material agreement entered · Form 8-K
- Aug 5, 2026United Therapeutics Corporation Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jul 23, 2026On July 22, 2026, the Board of Directors (the Board ) of United Therapeutics Corporation (the Company ), acting upon the recommendation of its Nominating and Governance Committee, increased the size of the Board to 13 members and appointed Victor Dzau, M.D., to serve as a member of the Board.Director or officer change · Form 8-K
- May 6, 2026United Therapeutics Corporation Reports First Quarter 2026 Financial Results.Earnings release · press release
- Mar 30, 2026On March 30, 2026, United Therapeutics Corporation issued a press release announcing positive results of the TETON-1 clinical study of Tyvaso ® (treprostinil) Inhalation Solution in patients with idiopathic pulmonary fibrosis.Other event · Form 8-K
- Mar 9, 2026On March 8, 2026, the Board of Directors (the Board ) of United Therapeutics Corporation (the Company ) approved a share repurchase program (the Share Repurchase Program ), authorizing the purchase by the Company of up to $2.0 billion of the Company’s common stock ( Common Stock ) before March 9, 2027.Material agreement entered · Form 8-K
- Mar 2, 2026United Therapeutics Corporation Announces Ralinepag.Regulation FD disclosure · press release
- Feb 25, 2026United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
- Jan 22, 2026On January 21, 2026, the Board of Directors (the “Board”) of United Therapeutics Corporation (the “Company”), acting upon the recommendation of its Nominating and Governance Committee, increased the size of the Board to 13 members and appointed Kevin J. Tracey, M.D., to serve as a member of the Board.Director or officer change · Form 8-K
- Oct 29, 2025United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Drug Manufacturers, Specialty & Generic
Ranks #2 of 41 by RyuScore